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and prevent crucial activating interactions
with the ST2 receptor.
But when is IL-33 secreted? Unlike
IL-1b, which is readily secreted by
macrophages and dendritic cells after
stimulation with LPS and PMA, IL-33 re-
mained intracellular (Lu¨thi et al., 2009). In
apoptotic macrophages, caspase-medi-
ated processing ensured inactivation of
IL-33, but the processing fragments
were nevertheless kept cell associated.
In contrast, most IL-33 was released
from macrophages induced to undergo
necrotic cell death (Lu¨thi et al., 2009). As
expected, IL-33 was not processed in
necrotic endothelial cells (Cayrol and Gir-
ard, 2009) because caspases are not acti-
vated during this cell death process.
Together, these findings suggest that
IL-33 is specifically released during
necrotic cell death, which is thought to
be associated with tissue damage during
trauma or infection. Under these condi-
tions, extracellular IL-33 may engage the
ST2 receptor on mast cells and other
immune cells in order to alert the immune
system of tissue damage and infection
and to promote the initiation of healing
responses (Figure 1). In support of this
hypothesis, IL-33 is highly expressed in
endothelial cells of most organs and in
the epidermal and gastrointestinal epithe-
lium (Moussion et al., 2008). These tissues
may become exposed to pathogens,
allergens, and other environmental agents
that can trigger tissue damage. In this
respect, IL-33 appears highly reminiscent
of IL-1a and HMGB1, two dual-function
proteins that play important roles as
both intracellular nuclear proteins and
extracellular cytokines. Moreover, all
three proteins lack classical secretion
signals and display cytokine activity inde-
pendently of processing. In addition, all
three are released by necrotic cells,
but kept intracellular during apoptosis.
Because of these features, HMGB1 and
IL-1a have been referred to as ‘‘endoge-
nous danger signals’’ or ‘‘alarmins.’’ The
work by Lu¨thi et al. (2009) now also
bestows IL-33 with this title.
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Adenoviral vectors used in gene therapy induce inflammation, although the underlying mechanisms are
currently unknown. In this issue of Immunity, Di Paolo et al. (2009) implicate interleukin-1a (IL-1a) in virus-
induced inflammation and identify the b3 integrin as the key receptor regulating IL-1a activity.
To combat invading viruses and survive
infection, eukaryotic hosts deploy an
arsenal of defensive measures. The first
of these is the innate immune system.
Innate immunity controls virus infection
and elicits the T and B cell responses of
adaptive immunity, which are required to
eliminate virus-infected cells. Several
classes of germline-encoded pattern
recognition receptors have been identi-
fied which recognize different compo-
nents of viruses. In most cases, viruses
are sensed via their genomes or their
replicative or transcriptional activities
(Pichlmair and Reis e Sousa, 2007). Toll-
like receptors 3, 7–8, and 9 recognize
dsRNA, ssRNA, and ssDNA respectively.
The cytosolic RNA helicases RIG-I and
MDA5 discriminate between different
classes of RNA viruses. RIG-I senses the
nascent 50 triphosphate moiety of viral
genomes or virus-derived transcripts of
negative-sense ssRNA viruses, whereas
MDA5 is activated by long dsRNA,
a typical intermediate of the replication
of plus-sense ssRNA viruses. The ge-
nome of DNA viruses are sensed byImmunity 31, July 17, 2009 ª2009 Elsevier Inc. 7
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tory factors, (DAI; also called DLM-1 or
ZBP1) or by absent in melanoma-2
(AIM2). TLRs, RNA helicases, and DAI
control transcription of inflammatory cyto-
kine and type I IFN genes, whereas AIM2
forms a caspase-1-activating inflamma-
some involved in the maturation of inter-
leukin-1b and IL-18. Members of the
NOD-like receptor family also form
inflammasomes and regulate IL-1b and
IL-18 in response to microbial products,
endogenous danger signals, and environ-
mental insults (Franchi et al., 2009).
Although the molecular sensors of virus
induced-interferon responses are well
defined, those regulating virus-induced
inflammation are poorly characterized.
This is particularly true in the case of
adenoviruses that are used in gene
therapy to deliver genes for the treatment
of both genetic and nongenetic deseases
(Muruve, 2004). An enduring problem with
Ad vectors is the systemic inflammatory
response, which contributes to significant
morbidity and mortality in transduced
hosts (Raper et al., 2002; Schnell et al.,
2001). The earliest events in infection
with Ad have been worked out and involve
the binding of Ad fiber coat protein to the
coxsackievirus and Ad receptor (CAR),
the primary attachment receptor for cell
infection for most Ad serotypes. Subse-
quently, RGD (Arg-Gly-Asp) motifs within
the viral penton base-coat protein interact
with integrins, allowing the internalization
of attached virus particles and triggering
of downstream signaling, the culmina-
tion of which is the transcription of proin-
flammatory cytokine and chemokine
genes. One such gene is interleukin-1
(IL-1). There are three members of the
IL-1 gene family: IL-1a, IL-1b, and IL-1
receptor antagonist (IL-1Ra) (Dinarello,
1996). IL-1a and IL-1b are agonists,
whereas IL-1Ra is a specific receptor
antagonist. All three bind the same
receptor, IL-1R1, and control production
of more proinflammatory cytokines and
chemokines, which drive inflammation.
Earlier work from Shayakhmetov and
colleagues using IL-1R-deficient mice
implicated IL-1 as a key factor driving
inflammation in vivo to adenoviral vectors.
Indeed, inhibition of IL-1 with IL-1ra
reduced hepatotoxicity without compro-
mising vector transduction into the liver
(Shayakhmetov et al., 2005). Under-
standing how IL-1 is regulated therefore8 Immunity 31, July 17, 2009 ª2009 Elsevierand its role in adenovirus-induced inflam-
mation is critical for the future of Ad-
based gene therapies to be realized. It is
also likely that IL-1 plays a role more
generally in the immune response to
viruses, particularly those associated
with an inflammatory response. Under-
standing how IL-1 is produced in virus-
infected cells will be important not only
for the development of therapeutic agents
to limit IL-1 production or action
in situations in which it is detrimental to
host survival but also to enhance IL-1
activity in order to boost innate immune
responses and host defenses.
In this issue of Immunity, Di Paolo et al.
(2009) have followed up on their earlier
studies and identified MARCO and
CD169-positive macrophages in marginal
zones of the spleen as IL-1a- and IL-1
b-producing cells in vivo. IL-1 is produced
very rapidly within 10 min after infection,
and production of IL-1 is dependent
on the interaction of the viral capsid
with macrophage receptors. Surprisingly,
macrophage-derived IL-1a and not IL-1b
was the factor responsible for IL-1RI-
dependent production of a cascade of
downstream proinflammatory cytokines
and chemokines in vivo. This is an
intriguing finding because IL-1a has been
implicated previously as a mediator of
sterile inflammation rather than a central
regulator of antimicrobial defenses (Chen
et al., 2007). In an effort to define the
receptors and downstream mechanisms
responsible for the IL-1a-mediated
response, the authors examined the role
of candidate pattern recognition receptors
previously implicated in adenoviral innate
defenses. Mice lacking TLR9- and the
NOD-like receptor family member NLRP3
did not show a defect in IL-1R1-driven
cytokine production. This latter result is
particularly surprising in light of Muruve
et al.’s recent study, which identified
NLRP3 as a critical sensor of adenovirus-
induced inflammation (Muruve et al.,
2008). In their study, Muruve et al. identi-
fied NLRP3 as a key regulator of
IL-1b production in adenovirus-infected
macrophages and the control of a
cascade of cytokines and chemokines
downstream of IL-1R1. Although both
studies identified IL-1b as a downstream
target of adenovirus infection, Di Paolo
et al. (2009) suggest that in vivo it is
IL-1a and not IL-1b that regulates the
IL-1R1-dependent response. In theirInc.studies, the induction of IL-1R1 target
genes was unaffected in mice lacking
NLRP3, as well as other components of
the NLRP3 inflammasome, apoptotic
speck protein containing a C-terminal
caspase recruitment domain (ASC), cas-
pase-1, and IL-1b itself, consistent with
this model. The discrepancy between
these two studies are however difficult to
reconcile on the basis of the present
data. Differences in the route of delivery,
the experimental readout, or the timing of
the analyses could contribute.
The importance of virus RGD motifs
and their interaction with macrophage b3
integrins was shown to be critical for
the IL-1a-IL-1R1-dependent inflammatory
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Figure 1. Model of Adenovirus-Induced
Inflammation
The interaction of components of adenovirus with
an unidentified pattern recognition receptor
induces signaling leading to transcription of pre-
IL-1a. NFkB activation is likely to mediate these
events. The association of b3 integrins with virus
RGD motifs then trigger intracellular signaling that
promotes virus internalization and processing of
pre-IL-1a. Pre-IL1a is processed into IL-1a-NTP
and mature IL-1a. The mature cytokine is released
from cells to trigger IL-1R1-dependent cytokine
and chemokine production. IL-1a-NTP translo-
cates to the nucleus and probably regulates addi-
tional target genes independently of IL-1R1. Viral
RGD-b3 integrin associations also lead to the
uptake of virus and rupture of endosomes, thereby
amplifying pre-IL1a gene transcription, synthesis,
and processing.
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Previewsresponse. Several RGD motif-interacting
integrins (v1, 31, v3, v5, v6, 51, M2, and
L2) have previously been shown to serve
as secondary receptors promoting Ad
internalization into different cell types
in vitro. This study highlights the role of
b3 integrins not only for viral entry but
also for IL-1a-driven inflammation. Like
IL-1b, IL-1a is synthesized as a prepro-
tein, pre-IL-1a (Dinarello, 1996); however,
unlike IL-1b, IL-1a is not processed by
caspase-1-containing inflammasomes.
Rather, pre-IL1a is processed in the cyto-
plasm by neutral proteases, including cal-
pains, thereby leading to the translocation
of the N-terminal IL-1a propiece (IL-1a-
NTP) to the nucleus, whereas mature
IL-1a is released from the cell. Staining
of spleen sections indicated that IL-1a
was primarily localized to the nuclei of in-
fected cells, suggesting that IL-1a was
processed in adenovirus-infected cells.
Adenovirus-induced Il1a gene transcrip-
tion and synthesis occurred normally in
b3-integrin-deficient mice; however, pre-
IL1a was not detected in the nucleus.
Therefore, the b3 integrin pathway
appears to regulate pre-IL-1a processing
rather than transcription of the IL-1a gene.
The role of b3 integrin in regulating IL-1a
activity is shown in Figure 1. Viral RGD-
b3 integrin associations also lead to the
uptake of virus and rupture of endo-
somes, thereby amplifying Il1a gene tran-How to be Naive
Jens V. Stein1,*
1Theodor Kocher Institute, University of Bern,
*Correspondence: jstein@tki.unibe.ch
DOI 10.1016/j.immuni.2009.06.010
The transcription factor KLF2 direc
issue of Immunity, Weinreich et al.
which otherwise induces CXCR3 ex
The adaptive immune system faces
a formidable logistic challenge, which is
to respond quickly to an invading path-
ogen while maintaining a large repertoire
of different antigen (Ag)-specific lympho-
cytes. Thus, only few T cells are ablescription, synthesis, and processing. How
pre-IL-1a processing is regulated and the
role of calpain in these events will require
follow-up studies. It will be intriguing to
examine IL-1a and cellular integrins
further in innate immunity to other viruses
and bacterial pathogens. Moreoever,
defining the relative role of the N-terminal
IL-1a propiece and the mature IL-1a
released from cells will likely uncover
novel roles for this cytokine in host-
defense and pathogenesis.
Adenoviral vectors induce significant
inflammation and overcoming this
obstacle will be important for the full
potential of this approach to be realized.
The discovery of the b3-integrin-depen-
dent IL-1a pathway as the primary medi-
ator of inflammation in vivo identifies
a pathway that could be targeted thera-
peutically to overcome this obstacle. A
feasible strategy could be to modify the
viral capsid to alleviate b3-integrin-driven
inflammation. Additionally, the inclusion
of immunomodulatory genes in gene
therapy vectors that interfere with b3-
integrin signaling, with IL-1a production
and/or with IL-1a-IL1R1 function, could
also be a worthwhile endeavor. Notably,
inflammation driven by adenoviral vectors
is not always a bad thing and could
be beneficial and desirable in certain
instances; for example, the ability of the
viral vector to trigger IL-1a-driven inflam-Freiestr. 1, 3012 Bern, Switzerland
ts expression of receptors involved i
(2009) demonstrate that KLF2 addi
pression.
to recognize and become activated by a
given Ag derived from microbial intruders,
whereas microbes may enter the body
through any epithelial surface, such as
skin, lungs, or gastrointestinal tract. To
meet this challenge, a surveillance system
Immmation could be useful in vaccine devel-
opment or cancer gene therapy in which
inflammation is a desirable adjuvant or
bystander effect.
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